Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-02
2007-10-02
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
10931285
ABSTRACT:
This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
REFERENCES:
patent: 4959314 (1990-09-01), Mark et al.
patent: 6335170 (2002-01-01), Orntoft
patent: 6387638 (2002-05-01), Ballinger et al.
patent: 6544759 (2003-04-01), Harari et al.
patent: 6936417 (2005-08-01), Orntoft
patent: 6949245 (2005-09-01), Sliwkowski
patent: 7041292 (2006-05-01), Sliwkowski
patent: 2003/0084924 (2003-05-01), Sliwkoski
patent: 2003/0201075 (2003-10-01), Wang
patent: 2004/0013667 (2004-01-01), Kelsey et al.
patent: 2004/0121326 (2004-06-01), Harari et al.
patent: 2005/0208043 (2005-09-01), Adams et al.
patent: 2005/0238640 (2005-10-01), Sliwkoski
patent: 2006/0034842 (2006-02-01), Adams et al.
patent: 2006/0073143 (2006-04-01), Adams et al.
patent: 2006/0083739 (2006-04-01), Sliwkoski
patent: 2006/0134682 (2006-06-01), Roberts et al.
patent: 2006/0193854 (2006-08-01), Adams et al.
patent: 2006/0198843 (2006-09-01), Adams et al.
patent: 2006/0216285 (2006-09-01), Adams et al.
patent: 2007/0009530 (2007-01-01), Altaba et al.
patent: WO 9805761 (1998-02-01), None
patent: WO-99/02681 (1999-01-01), None
patent: WO 9918976 (1999-04-01), None
patent: WO 9965924 (1999-12-01), None
patent: WO 0052204 (2000-09-01), None
patent: WO 0100238 (2001-01-01), None
patent: WO 0100245 (2001-01-01), None
Colman et al., Research in Immunology (145(1):33-36, 1994.
Abaza et al., Journal of Protein Chemistry (11(5):433-444, 1992.
Lederman et al ., Molecular Immunology (28:1171-1181, 1991.
Harari et al.,Neuregulin-4: A Novel Growth Factor that Acts Through the ErB-4 Receptor Tyrosine Kinase, Oncogene, 18:2681-2689, 1999.
Ben-Baruch et al.,Developmental and Physiologic Roles of ErbB Receptors and Their Lighands in Mammals, Hormones and Growth Factors in Development and Neoplasia, Wiley-Liss, Inc., Academic Publishers: Boston; Chapter 8:145-168, 1998.
Pinkas-Kramarski et al.,ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network, Molecular and Cellular Biology, 18(10):6090-6101, 1998.
Shelly et al.,Epiregulin is a Potent Pan-ErbB Ligand that Preferentially Activates Heterodimeric Receptor Complexes, J. Biol. Chem., 273(17):10496-10505, 1998.
Burden et al.,Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis, Neuron, 18:847-855, 1997.
Carraway III et al.,Neuregulin-2, a New Ligand of ErbB3/ErbB4-Receptor Tyrosine Kinases, Nature, 387:512-516, 1997.
Carroll et al.,Expression of Neuregulins and Their Putative Receptors, ErbB2 and ErbB3, is Induced During Wallerian Degeneration, The Journal of Neuroscience, 17(5):1642-1659, 1997.
Zhang et al.,Neuregulin-2(NRG3):A Novel Neural Tissue-Enriched Protein that Binds and Activates ErbB4, Proceedings of the National Academy of Science, 94:9562-9567, 1997.
Carraway III,Involvement of the Neuregulins and Their Receptors in Cardiac and Neural Development, BioEssays, 18(4):263-266, 1996.
Sepp-Lorenzino et al.,Signal Transduction Pathways Induced by Heregulin in MDA-MB-453 Breast Cancer Cells, Oncogene, 12:1679-1687, 1996.
Carraway III et al.,Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2
eu and erbB3, The Journal of Biological Chemistry, 270(13):7111-7116, 1995.
Carraway III et al.,Neuregulins and Their Receptors, Current Opinion in Neurobiology, 5:606-612, 1995.
Gassmann et al.,Aberrant Neural and Cardiac Development in Mice Lacking the ErbB4 Neuregulin Receptor, Nature, 378:390-394, 1995.
Lee et al.,Requirement for Neuregulin Receptor erbB2 in Neural and Cardiac Development, Nature, 378:394-398, 1995.
Meyer et al.,Multiple Essential Functions of Neuregulin in Development, Nature, 378:386-390, 1995.
Morrissey et al.,Axon-Induced Mitogenesis of Human Schwann Cells Involves Heregulin and p185erbB2, Proceedings of the National Academy of Science USA, 92:1431-1435, 1995.
Pinkas-Kramarski et al.,Diversification of Neu Differentiation Factor and Epidermal Growth Factor Signaling by Combinatorial Receptor Interactions, EMBO Journal, 15:2452-2467, 1995.
Pinkas-Kramarski et al.,Brain Neurons and Glial Cells Express Neu Differentiation Factor/Heregulin: A Survival Factor for Astrocytes, Proceedings of the National Academy of Science USA, 91:9387-9391, 1994.
Tzahar et al.,ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/Heregulin Isoforms, The Journal of Biological Chemistry, 269(40):25226-25233, 1994.
Peles et al.,Neu and its Ligands: From an Oncogene to Neural Factors, BioEssays, 15(12):815-824, 1993.
Creighton,Proteins, W. H. Freeman and Co., 1984.
GenBank Accession No. AA238077 dated Mar. 3, 1997, 2 pages.
Harari, D., et al., “Neyregulin-4: a novel growth factor that acts throgh the ErbB-4 receptor tyrosine kinase”, Oncogene (1999) 18, pp. 2681-2689.
Starr, A., et al., “ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy”, Cancer Cell Biology, 12 pages.
Yeda Research and Development Co., Ltd., “Neuregulin-4 (NRG4), a Novel growth Factor Which Acts Throgh the Erbb4 Receptor Tyrosine Kinase; Sequences, Antibodies To and Uses Thereof.” http://www.yedarnd.com/opportunities/?id=1236&act=print.
Anderson (Nature 1998; 392(Supp); 25-30).
Burgess et al., J Cell Biol. 111:2129-2138, 1990.
Lazar et al., Mol Cell Biol. 8:1247-1252, 1988.
Mikayama et al. (PNAS, 1993, 90: 10056-10060).
Ngo et al., in “The Protein Folding Problem and Tertiary Structure Prediction”, 1994 (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Skolnick and Fetrow (Trends in Biotechnology, 2000. 18(1): 34-39).
Spitler LE (Cancer Biotherapy 1995: 10(1); 1-3).
Cen Hui
Kavanaugh W. Michael
Lee Pauline
Alexander Lisa E.
Belyavskyi Michail A.
Chan Christina
Chiron Corporation
Harbin Alisa A.
LandOfFree
Antibodies to EGFH2 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to EGFH2 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to EGFH2 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895988